Quick answer
In the Neo-Healer/BCTOP-H-N01 Phase III trial, led by Fudan University Shanghai Cancer Center's Shao Zhimin across 61 Chinese hospitals, giving anbenitamab (KN026, a biparatopic antibody binding two ERBB2 sites) with HB1801 (a solvent-free, albumin-bound docetaxel), with or without carboplatin, before surgery raised total pathological complete response (tpCR) to 62.4% versus 51.2% for standard trastuzumab plus pertuzumab and docetaxel (THP), in ERBB2-positive breast cancer [1][3].
Key takeaways
- HER2-positive breast cancer is about 15–20% of cases and more aggressive; neoadjuvant THP dual blockade plus chemotherapy is the standard [4].
- Across 521 patients, tpCR was 62.4% with anbenitamab plus HB1801 versus 51.2% with THP — an 11.4 percentage-point gain (95% CI 3.2–19.6; P=0.004) [3].
- Benefit was consistent across prespecified subgroups, and safety was comparable: grade 3–4 treatment-related adverse events were 29.3% versus 28.3% [3].
- The results were reported at ASCO 2026 as a late-breaking abstract and published in JAMA Oncology in September 2026 [1][4].
- It is a new neoadjuvant option for ERBB2-positive disease, raising pathological response before surgery [1].
The trial and the drugs
Neoadjuvant therapy — treatment before surgery — is standard for stage II and III HER2-positive breast cancer, and achieving a pathological complete response at surgery signals better long-term outcomes. Standard dual blockade combines trastuzumab and pertuzumab with a taxane; many patients still do not reach pCR, so stronger regimens are needed [3][4].
Anbenitamab binds two different ERBB2 epitopes for stronger receptor blockade; HB1801 is a solvent-free, albumin-bound docetaxel that avoids the solvents of conventional taxanes. The trial compared six cycles of this regimen (± carboplatin) with standard THP (± carboplatin) [1][3].
What the trial found
Blinded independent review showed a tpCR of 62.4% versus 51.2%, with the confidence interval excluding zero and a P value of 0.004. Serious diarrhoea was reportedly much less frequent with the new regimen, and overall grade 3–4 toxicity was similar to standard therapy [1][3].
Pathological complete response is a validated early signal, but it is not the same as long-term survival. Event-free and overall survival follow-up are still needed before this becomes a standard of care, and cost and access will matter [1][3].
The condition in context: ERBB2-positive breast cancer
HER2-positive breast cancer is an aggressive subtype, but dual antibody therapy has transformed its outlook over the past two decades.
| Region | What the data shows | Source |
|---|---|---|
| Worldwide | Breast cancer is the most common cancer in women, with about 2.3 million new cases a year [5]. | World Health Organization [5] |
| Subtype | HER2-positive disease is about 15–20% of breast cancers and is more aggressive [4]. | Liangyihui / trial commentary [4] |
| China | Neo-Healer ran across 61 Chinese hospitals with 521 patients, led by Fudan's Shao Zhimin [1][3]. | Media / JAMA Oncology [1][3] |
Because HER2-positive disease is common and aggressive, a regimen raising pCR by more than 11 points could affect many patients — if survival data confirm the benefit [1][3].
Why it matters
| Potential | What the report suggests | Source |
|---|---|---|
| Efficacy | tpCR rose to 62.4% from 51.2%, a sizeable gain [3]. | [3] |
| Tolerability | Grade 3–4 toxicity was similar, with less serious diarrhoea [1][3]. | [1][3] |
| Caution | Survival data are pending; pCR is a surrogate endpoint [1]. | [1] |
Availability and limits
- This is an editorial summary of journal and media reports, not an independent clinical assessment or a booking channel [1][2][3].
- The benefit shown is pathological complete response, a surrogate; survival results are not yet available [1][3].
- The regimen is specific to ERBB2-positive early/locally advanced disease and a clinical trial setting [3].
- Drug availability, regulatory status and cost vary by country [1].
- Burden figures describe breast cancer generally and come from WHO, not this trial [5].
What to ask before booking
| Question | Why it matters |
|---|---|
| Is my tumour ERBB2-positive and is neoadjuvant therapy appropriate? | The regimen applies to stage II/III ERBB2-positive disease [3]. |
| Is anbenitamab plus HB1801 available outside a trial? | It is a trial-reported regimen; availability and approval vary [1]. |
| Which department handles foreign patients, and in what language? | Fudan Cancer Center is a working hospital we do not book; confirm international-department coordination and language support. |
| How are neoadjuvant cycles, surgery and follow-up scheduled around travel? | Neoadjuvant care spans months; plan cycles, surgery and review. |
Questions patients ask
What is the Neo-Healer trial?
A multicentre, open-label, randomised Phase III trial led by Fudan's Shao Zhimin across 61 Chinese hospitals, comparing neoadjuvant anbenitamab plus HB1801 (± carboplatin) with standard THP (± carboplatin) in ERBB2-positive breast cancer [1][3].
What were the results?
Total pathological complete response was 62.4% with the new regimen versus 51.2% with THP — an 11.4 percentage-point gain (P=0.004) — with similar grade 3–4 toxicity [3].
What are anbenitamab and HB1801?
Anbenitamab (KN026) is a bispecific antibody binding two ERBB2 epitopes; HB1801 is a solvent-free, albumin-bound docetaxel [1][3].
Does higher pCR mean longer survival?
Not automatically. pCR is a validated early signal, but event-free and overall survival data are still needed [1].
Is this relevant to international patients considering breast-cancer care in China?
It is useful context for China's breast-cancer research. Fudan Cancer Center is a working hospital we do not book — contact its international department directly and confirm candidacy, language support and travel logistics [1][4].